Italian pharmacy online: cialis senza ricetta medica in farmacia.

Novartis first half 2001 background slides

Investor Relations
Background Information
Half Year 2001 Results
August 2001
Overview
Solid Growth Trend in Pharmaceuticals Drives
Group Sales
Sales: CHF 15.5 bn, +12% in local currencies, +11% in CHF
Sales growth in % (LC)
Sales by region in %
Pharmaceuticals
Asia/Australia/
Generics1
Consumer Health
CIBA Vision1
Rest of the
Americas
Animal Health
1 Including acquisition benefits
First Half Operating Income up 7% to CHF 3.5 bn
Operating income1 growth
Operating income by sector4
in % (CHF)
Pharmaceuticals
Pharmaceuticals
Generics2
Consumer Health
CIBA Vision3
Generics 4%
Animal Health
Consumer
Animal CIBA
Health Vision
-35% -25% -15% -5% 5% 15%
1 Continuing activities
2 Including acquisition effects
3 Including Wesley Jessen integration costs of CHF 31 m
4 Excluding corporate and other expenses
Group Operating Margin Lowered due to Significant
Investments in Pharmaceutical Marketing & Sales
23.4 22.5
Generics
Consumer
ceuticals
1 Excluding exceptionals associated with Wesley Jessen of CHF 31 m
Highlights Half Year 2001
Major Approvals/ − Femara® 1st line in US
Launches:
− Starlix® in US and EU
− Zometa® in EU for HCM
− Gleevec™/Glivec® in > 10 countries
− Foradil® in US
− Riamet® in EU
− Visudyne™ in EU for expanded use
Delays:
− Zelmac®/Zelnorm™
− Xolair®
Filings:
− Diovan® in US (priority review) and EU for
heart failure
− Glivec® in EU and Japan
− Elidel™ in EU for atopic eczema
Key Financials
Sustained Growth First Half 2001
Key Figures for Continuing Activities
Operating income
as a % of sales
22.5
23.4
Net income
as a % of sales
24.1
24.3
EPS (CHF)
Free cash flow
as a % of sales
0.7
2.2
Number of employees
Sales Growth First Half 2001
Driven by Volume and Acquisitions
Acq./Div.
Currency
Operating Costs – Increased Marketing to Support
Product Launches and Expansions
H1/2001 CHF m
Change in % in CHF
Cost of goods sold
Marketing & Distribution
Research & Development
General & Administration
Operating income
-20% -10%
Strong Balance Sheet –
Debt/Equity Ratio 21%
Liquid funds of CHF 15.1 bn
Debt/Equity Ratio
Dec-1999
Jun-2000
Dec-2000
Jun-2001
Net liquidity of CHF 7.3 bn
Dec-1999
Jun-2000
Dec-2000
Jun-2001
Dec-1999
Jun-2000
Dec-2000
Jun-2001
Pharmaceuticals
Pharmaceuticals – Continued Strong Growth
Pharmaceutical sales posted 13% growth (in LC) driven by in-
market products (Diovan®, Lotrel®, Lamisil®, Exelon®)
Continued strong performance coming from US business with
21% growth (in LC)
Excluding Famvir®/Denavir® and the transfer of Ophthalmic to
Pharmaceuticals, growth would have been (in LC)
10% world-wide
15% in US

Pharmaceuticals Top 20 Products I
Total Sales Growth
Total sales in CHF m
Growth in %
first half
Sandimmun®/Neoral®
Diovan®/Co-Diovan®
Cibacen®/Lotensin®
of which Lotrel®
Aredia®
Lamisil®
Voltaren®
Sandostatin®
Miacalcic®
Lescol®
Tegretol®
1 Corrected for inter-sectorial transfers
Pharmaceuticals Top 20 Products II
Total Sales Growth
Total sales in CHF m
Growth in %
first half
Leponex®/Clozaril®
Estraderm® (group)
Exelon®
Foradil®
Famvir® /Denavir®
Visudyne®
Nitroderm TTS®
Zaditen®
Parlodel®
Desferal®
1 Corrected for inter-sectorial transfers
15 2 Includes Meri range & Estalis
Sandimmun®/Neoral® –
Slow Generic Erosion in US
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Sandimmun®/Neoral®
Warfarin
TRx Erosion % 50%
Azathioprine
Note: Month 1 is May 2000
Diovan® – On Its Way to Share Leadership in US
US Category NRx Share:
First half 2001 w-w sales:
% Jan. 1998 to June 2001
CHF 806 m, +53% LC
(US: +40% LC)
Continues to outpace the ARB
market segment (+47% w-w)
On track to take category
Losartan 36.7%
leadership position in US: NRx
share at 34.2%
Recently published MARVAL trial
Diovan® 34.2%
demonstrates efficacy in microal-
buminuria
Only ARB to show CHF benefits;
sNDA filed in April 2001
– priority
review received in June (US)
Source: IMS Health, NPA weekly, NRx share in ARB segment
Lotrel® – Strong Continued Growth
+47% Growth in First Half 2001
Lotrel® vs Amlodipine
New Prescription Share (in %)
First half ‘01 sales:
CHF 346 m, +47% LC
Significantly outpaced
competition
Patent extension to 2017
1 According to internal data
Source: IMS Health, NPA Plus, NRx share in amlodipine segment
Novartis Has the Two Fastest Growing Brands in
the Top 10 Anti-Hypertensives in the US
Product June NRx (MAT-IMS) % Growth
1. Norvasc
2. Zestril/Zestoretic
3. Prinivil/Prinzide
5. Toprol-XL
4. Accupril/Accuretic
6. Cozaar/Hyzaar
7. Diovan/Diovan HCT
3.68 m
39.6%
8. Lotensin/Lotensin HCT
3.36 m
-0.5%
9. Monopril/Monopril HCT
10. Lotrel*
2.29 m
46.4%
*Lotrel has just recently entered the top ten list
Lamisil® Expanded Leadership Position1
CHF 624 m, +18% in LC
DTC campaign launched
Lamisil Oral
DTC campaign
launched
Labeling change in US
Sporanox
negatively affected Q2 sales 40%
Expansion of segment
leadership
Jan 98 Jul 98 Jan 99 Jul 99 Jan 00 Jul 00 Jan 01
Source: IMS Health, NPA Plus,
1 NRx share in Onychomycosis segment

Trileptal® – Most Successful Anticonvulsant
NRx Volume (000s)
Trileptal®
Neurontin
Lamictal
Zonegran
Gabitril
Months on
the market
9 10 11 12 13 14 15
Source: IMS NPA; 5-15-01
Exelon® – Strong Share Position
Alzheimer’s Disease:
Exelon® Total Rx Share in US (in %)
Source: IMS NPA Plus 7/TRx monthly
VisudyneTM – Record Breaking Launch
2001
First half sales CHF 178 m
Reimbursement in most
countries
Expanded reimbursement in EU
Indication for pathologic myopia
Approved in EU in March 2001
FDA approvable letter
Launches and Brand Expansions
Gleevec™/Glivec®
Beat expectations with CHF 58 m in sales
Positive recommendation in Europe, launch expected in Q4
Femara®
Market segment share gains, US NRx share 34% in June 01
CHF 92 m, +64% in LC
Starlix®
US NRx trend flat
Foradil®
Significantly beaten Beta-2 market segment growth with
+24% in LC
Launched in US (May), targeting specialists
Pharmaceutical Pipeline
>20031
Starlix®
ElidelTM
ZelnormTM 2/Zelmac®
Zometa®
Certican®
Zomaril®
Foradil®
GleevecTM/Glivec®
GleevecTM/Glivec® J
Lamisil®
Foradil® US
Apligraf® EU
OctreoTherTM
Tinea capitis
Estalis®
Ritalin® LA
Osteoporosis
Femara®
GleevecTM/Glivec®
Foradil®
Diovan®
Zometa®
Bone met.
Lamisil®
Syst. myc.
Co-Diovan®
Xolair® 4
High dose
ZelnormTM 2/Zelmac®
NME roll-out
LCM indication
ZelnormTM 2/Zelmac®
1 Major projects only
ZelnormTM 2/Zelmac®
2 Timing subject to result of appeal
3 Out-licensed to Speedel, call back option for Novartis
Diovan®
4 Subject to further discussion with health authorities
Appendix
First Half 2001 Sales
Growth Components by Sector
Acq./Div.
Currency
Pharmaceuticals
Generics
Consumer Health
CIBA Vision
Animal Health
Sales 2nd Quarter 2001 by Sector
Growth in %
Q2 2001 Q2 2000
Pharmaceuticals
Generics
Consumer Health
CIBA Vision
Animal Health
Continuing
activities
Development of Major Currencies
Against CHF
Average rates
Average rates
first half 2001 first half 2000
Sales Performance of Recently Launched
Pharmaceutical Products
H1 Sales in CHF m
Comtan®
Femara®
Gleevec™
Starlix®
Trileptal®
Zometa®
Pharmaceuticals
Top 20 Products
Sales Performance First Half 2001
Pharmaceuticals Top 20 Products I
US Sales Growth
US Sales in CHF m
LC Growth
first half
Sandimmun®/Neoral®
Diovan®/Co-Diovan®
Cibacen®/Lotensin®
of which Lotrel®
Aredia®
Lamisil®
Voltaren®
Sandostatin®
Miacalcic®
Lescol®
Tegretol®
Pharmaceuticals Top 20 Products II
US Sales Growth
US Sales in CHF m
LC Growth
first half
Leponex®/Clozaril®
Estraderm®
Exelon®
Foradil®
Famvir® /Denavir®
Visudyne®
Nitroderm TTS®
Zaditen®
Parlodel®
Desferal®
Pharmaceuticals Top 20 Products I
RoW Sales Growth
RoW Sales in CHF m
LC Growth
first half
Sandimmun®/Neoral®
Diovan®/Co-Diovan®
Cibacen®/Lotensin®
of which Lotrel®
Aredia®
Lamisil®
Voltaren®
Sandostatin®
Miacalcic®
Lescol®
Tegretol®
Pharmaceuticals Top 20 Products II
RoW Sales Growth
RoW Sales in CHF m
LC Growth
first half
Leponex®/Clozaril®
Estraderm®
Exelon®
Foradil®
Famvir® /Denavir®
Visudyne®
Nitroderm TTS®
Zaditen®
Parlodel®
Desferal®
Pharmaceuticals
Top 20 Products I
Market segment
Sandimmun®/Neoral®
Transpl., RA, Psoriasis
Diovan®/Co-Diovan®
Hypertension
Cibacen®/Lotensin®
Antihypertensives
Aredia®
Oncology (Bone)
Lamisil®
Fungal infections
Voltaren®
Antirheumatics
Sandostatin®
Acromegaly
Miacalcic®
Osteoporosis
Lescol®
Cholesterol reduction
Tegretol®
Epilepsy
Pharmaceuticals
Top 20 Products II
Market segment
Leponex®/Clozaril®
Schizophrenia
Exelon®
Alzheimer’s disease
Estraderm®
Hormone replacement
Foradil®
Asthma, Bronchitis
Famvir®
Acute herpes zoster
Visudyne®
Pathologic myopia
Nitroderm TTS®
Angina pectoris
Zaditen®
Asthma, Allergy
Parlodel®
Parkinson’s
Desferal®
Oncology/hematology

Source: http://www.equitystory.com/Download/Companies/novartis/Quarterly%20Reports/novartis_qr_2_01_bg_slides.pdf

ssc.govt.nz

Office of the Minister of State Services Chair Cabinet Committee on State Sector Reform and Expenditure Control Future monitoring of the Accident Compensation Corporation and Housing New Zealand Corporation Proposal This paper outlines a recent decision by relevant Ministers to transfer monitoring of the Accident Compensation Corporation (ACC) and Housing New Zealand Corporation (HNZC)

gpcahealth.org

GPCA Health Committee INFLAMMATORY BOWEL DISEASE (IBD) - 2011 OVERVIEW: This is a group of diseases of the small and large intestine, characterized by chronic and protracted diarrhea, malabsorption, weight loss, anemia, and malnutrition. They are all treatable, but seldom cured. In each specific disease, a different type of inflammatory cell is found in large numbers in the l

Copyright © 2010-2014 Pharmacy Drugs Pdf